Stocks · News reference
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Invesco's assets under management rose 4.7% in August 2026 to $2.56 trillion, driven by $49 billion in market gains and $27.6 billion in long-term net inflows. ETFs, QQQ, and liquidity products led growth, with QQQ AUM climbing 8% and liquidity AUM rising 15.6%. The company's strong first-half momentum and diversified investment platform position it well for continued asset gathering.
Financial education platform Funkled has partnered with advice technology provider Focus to integrate digital client engagement tools directly into its free learning platform. Starting August 1st, Funkled will launch a 30-day content programme with daily modules and podcasts covering financial topics, aiming to address the UK's advice gap where only 8.7% of adults take financial advice.
Invesco senior managing director Jeffrey H. Kupor sold 26,002 shares valued at $702,314 on July 2, 2026, but this was a non-discretionary tax withholding event related to restricted stock unit vesting, not a voluntary sale. The transaction is insignificant for investors to monitor. More importantly, Invesco posted its 11th consecutive quarter of positive organic growth with $22 billion in net inflows, $2.2 trillion in assets under management, and raised its dividend while authorizing a $1 billion buyback.
The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.
Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $130 to $137.
Filed: 2026-09-21 AccNo: 0001070081-26-000023 Size: 190 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits